Forbion Logo
Forbion raises in excess of €2 billion for two new funds
October 15, 2024 01:00 ET | Forbion
Forbion’s largest fundraising to date with Forbion’s Growth Opportunities Fund III raising €1.2 billion & Forbion Ventures Fund VII raising €890 million
Inventiva annonce un
Inventiva annonce un financement allant jusqu’à 348 millions d'euros afin d’avancer l’étude NATiV3 de Phase 3 dans la MASH
October 14, 2024 02:30 ET | INVENTIVA
► Inventiva obtient 94,1 millions d’euros dans le cadre d’un financement en plusieurs tranches d'un montant maximum de 348 millions d'euros, sous réserve de la réalisation de certaines conditions,...
Inventiva announces
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
October 14, 2024 02:30 ET | INVENTIVA
Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million...
Tourmaline_logo.jpg
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
October 11, 2024 07:30 ET | Tourmaline Bio, Inc.
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
Turnstone Logo.jpg
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
October 11, 2024 06:00 ET | Turnstone Biologics Corp.
Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway.
Upstream Bio Announces Pricing of Upsized Initial Public Offering
October 10, 2024 19:35 ET | Upstream Bio
Upstream Bio announces pricing of upsized initial public offering
Logo_Pharming_original.png
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
October 10, 2024 01:00 ET | Pharming Group N.V.
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1...
Keck Graduate Instit
Keck Graduate Institute Ranked the #3 Master’s Program in the Nation for 2025
October 09, 2024 19:31 ET | Keck Graduate Institute
Claremont, CA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Keck Graduate Institute is one of the best places to get a master’s degree in the United States according to Intelligent.com’s recently released 2025...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
October 09, 2024 16:15 ET | Genelux Corporation
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
purespring logo.png
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 09, 2024 07:00 ET | Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...